The short version of thymosin beta-4 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-30. Anything still debated is marked as such rather than presented as settled.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
== External links == The MEROPS online database for peptidases and their inhibitors: SPP:A22.003, SPPL2a: A22.007, SPPL2b:A22.004, SPPL2c:A22.006, SPPL3:A22.005 UMich Orientation of Proteins in Membranes families/superfamily-178 - Calculated spatial position of type 1 signal peptidase in membrane signal+peptide+peptidase at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Dermal and subcutaneous growths result from (1) reactive or neoplastic proliferation of cellular components of the dermis or subcutaneous tissue, or (2) neoplasms invading or aberrantly present in the dermis.
=== Interpretation === The prothrombin time is the time it takes plasma to clot after addition of tissue factor (obtained from animals such as rabbits, or recombinant tissue factor, or from brains of autopsy patients). This measures the quality of the extrinsic pathway (as well as the common pathway) of coagulation. The speed of the extrinsic pathway is greatly affected by levels of functional factor VII in the body. Factor VII has a short half-life and the carboxylation of its glutamate residues requires vitamin K. The prothrombin time can be prolonged as a result of deficiencies in vitamin K, warfarin therapy, malabsorption, or lack of intestinal colonization by bacteria (such as in newborns). In addition, poor factor VII synthesis (due to liver disease) or increased consumption (in disseminated intravascular coagulation) may prolong the PT. The INR is typically used to monitor patients being treated with anticoagulants of the vitamin K antagonist type, such as warfarin. However, prothrombin time and INR are insufficient for monitoring therapy with direct oral anticoagulants (DOACs). The normal range for a healthy person not using warfarin is 0.8–1.2, and for people on warfarin therapy an INR of 2.0–3.0 is usually targeted, although the target INR may be higher in particular situations, such as for those with a mechanical heart valve. If the INR is outside the target range, a high INR indicates a higher risk of bleeding, while a low INR suggests a higher risk of developing a clot.
The prime ministers of Equatorial Guinea, Mozambique, Namibia, Peru, and Uganda are included in the list of elected or appointed female deputy heads of government but not in the list of elected or appointed female deputy heads of state, as they are neither heads of government, nor deputy heads of state due to the existence of the office of vice president in these countries, whereas the prime ministers of South Korea and Sri Lanka (post-1978) are included in both of those lists. Currently, Iceland and Trinidad and Tobago are the only republics where both the serving head of state and head of government are women. Costa Rica, the Marshall Islands, Mexico, Namibia, Peru, Suriname, Tanzania, and Venezuela are republics where the female President is the combined head of state and government.
=== EC 2.10: metal transferases === The category of EC 2.10 includes enzymes that transfer molybdenum or tungsten-containing groups. However, as of 2011, only one enzyme has been added: molybdopterin molybdotransferase. This enzyme is a component of MoCo biosynthesis in Escherichia coli. The reaction it catalyzes is as follows: adenylyl-molybdopterin + molybdate
Sources: en.wikipedia.org
Patients should be advised to remove any medicated patch prior to an MRI scan and replace it with a new patch after the scan is complete. In 2009, an article in Europace journal detailed stories of skin burns that occurred with transdermal patches that contain metal (usually as a backing material) caused by shock therapy from external as well as internal cardioverter defibrillators (ICD).
=== Apodization in imaging === Since side lobes of the Airy disk are responsible for degrading the image, techniques for suppressing them are used. If the imaging beam has a Gaussian distribution, then when the truncation ratio (the ratio of the diameter of the Gaussian beam to the diameter of the truncating aperture) is set to 1, the side-lobes become negligible and the beam profile becomes purely Gaussian. In medical ultrasonography, the effect of grating lobes can be reduced by activating ultrasonic transducer elements using variable voltages in the apodization process.
=== Chief executives === 1907–1962, James E. "Jim" Casey 1962–1972, George D. Smith 1972–1973, Paul Oberkotter 1973–1980, Harold Oberkotter 1980–1984, George Lamb 1984–1989, John W. Rogers 1989–1996, Kent C. "Oz" Nelson 1997–2001, James P. Kelly 2002–2007, Michael L. "Mike" Eskew 2008–2014, Scott Davis 2014–2020, David Abney 2020–current, Carol B. Tomé
In the United States, dog foods labelled as "complete and balanced" must meet standards established by the Association of American Feed Control Officials (AAFCO), either by meeting a nutrient profile or by passing a feeding trial. The Dog Food Nutrient Profiles were last updated in 2016 by the AAFCO's Canine Nutrition Expert Subcommittee. Critics argue that due to the limitations of the trial and the gaps in knowledge within animal nutrition science, the term "complete and balanced" is inaccurate and even deceptive. An AAFCO panel expert has stated that "although the AAFCO profiles are better than nothing, they provide false securities." Certain manufacturers label their products with terms such as "premium", "ultra premium", "natural", and "holistic". Such terms currently have no legal definitions and are not regulated. There are also varieties of dog food labeled as "human-grade food." Although no official definition of this term exists, the assumption is that other brands use foods that would not pass US Food and Drug Administration inspection according to the Pure Food and Drug Act or the Meat Inspection Act. The ingredients on the label must be listed in descending order by weight before cooking. This means before all of the moisture is removed from the meat, fruits, vegetables and other ingredients used.
Sources: en.wikipedia.org
== Habitat and ecology == Nematophagous fungi occur in a variety of habitats including leaves entering the decomposition phase, soil samples that contain decomposed leaves or in soil samples from agricultural land and they can also be found in pasture land. The latter possibly relates to the tendency of this species to occur in dung of cow and sheep where its nematode hosts are abundant. The fungus is commonly found in tropical and warm climates. It is more commonly encountered in the spring and fall. The fungus has been isolated from include Brazil, China, Florida, New Zealand, and eastern Canada. The fungus tends to be more commonly reported from climate regions subject to monsoons and does not appear to survive cold weather well, though the predilection of this species for warm damp climates may relate more to the distributions of its hosts. The fungus is known primarily as a parasite of nematodes and eelworms. During its life cycle, conidia of the fungus are ingested by eelworms or nematodes and lodge in the pharynx or gut. Once inside the host, the conidia germinate and begin to colonize the host digestive tract. During the initial phases of this process, the host remains alive, but as the fungus spreads from the gut to the surrounding tissues in the latter stages of infection and the death of the host soon follows. Conidial production occurs on nematode cadavers by the eruption of conidiophores and conidia through the host cuticle.
The initialism for the ColdFusion Markup Language is CFML. When ColdFusion templates are saved to disk, they are traditionally given the extension .cfm or .cfml. The .cfc extension is used for ColdFusion Components. The original extension was DBM or DBML, which stood for Database Markup Language. When talking about ColdFusion, most users use the acronym CF and this is used for numerous ColdFusion resources such as user groups (CFUGs) and sites. CFMX is the common abbreviation for ColdFusion versions 6 and 7 (a.k.a. ColdFusion MX).
Notch signaling is triggered via direct cell-to-cell contact, mediated by interactions between the Notch receptor protein in the signal receiving cell and a ligand in an adjacent signal transmitting cell. These type 1 single-pass transmembrane proteins fall into the Delta/Serrate/Lag-2 (DSL) family of proteins which is named after the three canonical Notch ligands. Delta and Serrate are found in Drosophila while Lag-2 is found in C. elegans. Humans contain 3 Delta homologs, Delta-like 1, 3, and 4, as well as two Serrate homologs, Jagged 1 and 2. Notch proteins consist of a relatively short intracellular domain and a large extracellular domain with one or more EGF motifs and a N-terminal DSL-binding motif. EGF repeats 11-12 on the Notch extracellular domain have been shown to be necessary and sufficient for trans signaling interactions between Notch and its ligands. Additionally, EGF repeats 24-29 have been implicated in inhibition of cis interactions between Notch and ligands co-expressed in the same cell.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.